At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about how immunotherapy has influenced treatment for patients with bladder cancer.
CancerNetwork® spoke with Daniel P. Petrylak, MD, professor of medicine (medical oncology) and of urology and co-leader of Cancer Signaling Networks at Yale Cancer Center, about using maintenance immunotherapy as a standard of care for patients with bladder cancer. He spoke on the topic at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®), for which he served as meeting co-chair.
Immunotherapy is now considered standard of care for patients who respond to frontline chemotherapy for metastatic urothelial carcinoma. By respond, I define that as stable, complete, or partial response to chemotherapy, which could be either cisplatin and gemcitabine, carboplatin and gemcitabine, or the MVAC regimen [which includes methotrexate, vinblastine sulfate, doxorubicin hydrochloride, and cisplatin]. There’s a significant improvement in survival in those patients who receive maintenance of avelumab [Bavencio] compared with those who receive just best standard of care in that setting. We view that as standard treatment for these patients.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.